BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

Tempest Therapeutics (TPST)Tempest TherapeuticsFinancing

$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants BRISBANE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the

Related news

LYELLyell Immunopharma2026-11-04 14:02 EST

Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

TPSTTempest Therapeutics2026-10-14 12:00 EST

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

FATEFate Therapeutics2026-11-03 21:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

CMPXCompass Therapeutics2026-11-02 14:00 EST

Compass Therapeutics to Participate in Upcoming November Investor Events

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

View all latest news

Tempest Therapeutics

In Vivo CAR T Company Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles. CD7-Targeted Delivery Tempest's proprietary delivery system targets CD7-positive T cells...

Recent company news

TPSTTempest Therapeutics2026-10-14 12:00 EST

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

TPSTTempest Therapeutics2026-09-23 12:00 EST

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

TPSTTempest Therapeutics2026-09-15 20:05 EST

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

TPSTTempest Therapeutics2026-09-11 12:00 EST

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

TPSTTempest Therapeutics2026-09-08 12:30 EST

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close
0.38 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States